

Cite this: *Chem. Sci.*, 2021, 12, 12118 All publication charges for this article have been paid for by the Royal Society of Chemistry

# An endogenous stimulus detonated nanocluster-bomb for contrast-enhanced cancer imaging and combination therapy†

Huanhuan Sun, Wenjie Ma, Shuangdi Duan, Jin Huang, Ruichen Jia, Hong Cheng, Biao Chen, Xiaoxiao He\* and Kemin Wang \*

Exploitation of stimuli-responsive nanoplatforms is of great value for precise and efficient cancer theranostics. Herein, an *in situ* activable “nanocluster-bomb” detonated by endogenous overexpressing legumain is fabricated for contrast-enhanced tumor imaging and controlled gene/drug release. By utilizing the functional peptides as bioligands, TAMRA-encircled gold nanoclusters (AuNCs) endowed with targeting, positively charged and legumain-specific domains are prepared as quenched building blocks due to the AuNCs’ nanosurface energy transfer (NSET) effect on TAMRA. Importantly, the AuNCs can shelter therapeutic cargos of DNzyme and Dox (Dzs-Dox) to aggregate larger nanoparticles as a “nanocluster-bomb” (AuNCs/Dzs-Dox), which could be selectively internalized into cancer cells by integrin-mediated endocytosis and in turn locally hydrolyzed in the lysosome with the aid of legumain. A “bomb-like” behavior including “spark-like” appearance (fluorescence on) derived from the diminished NSET effect of AuNCs and cargo release (disaggregation) of Dzs-Dox is subsequently monitored. The results showed that the AuNC-based disaggregation manner of the “nanobomb” triggered by legumain significantly improved the imaging contrast due to the activable mechanism and the enhanced cellular uptake of AuNCs. Meanwhile, the *in vitro* cytotoxicity tests revealed that the detonation strategy based on AuNCs/Dzs-Dox readily achieved efficient gene/chemo combination therapy. Moreover, the super efficacy of combinational therapy was further demonstrated by treating a xenografted MDA-MB-231 tumor model *in vivo*. We envision that our multipronged design of theranostic “nanocluster-bomb” with endogenous stimuli-responsiveness provides a novel strategy and great promise in the application of high contrast imaging and on-demand drug delivery for precise cancer theranostics.

Received 15th July 2021  
Accepted 8th August 2021

DOI: 10.1039/d1sc03847h

rsc.li/chemical-science

## Introduction

“Stimulus-triggered cargo release” is a well-established strategy by now and has been broadly utilized as the foundation for precise and effective cancer theranostics.<sup>1–4</sup> Based on the internal or external stimulus, various types of nanomaterials have been developed as smart nanocarriers endowed with different cargo release mechanisms<sup>5–8</sup> including stimulus mediated direct release,<sup>9</sup> expansion,<sup>10</sup> gatekeeping,<sup>11</sup> cavitation<sup>11</sup> and disassembly/disaggregation.<sup>13–15</sup> Among them, destructive behavior like cavitation and disassembly/disaggregation has attracted much attention due to the high payload capacity, concentrated payload release and size-tunable

behavior of the nanomaterials,<sup>16</sup> endowing them with prolonged circulation lifetime,<sup>16</sup> enhanced localized cytotoxicity<sup>18</sup> and renal clearance efficiency.<sup>19</sup> The typical nanomaterials working in this manner are the polymersomes and liposomes, whose complex synthetic procedure or tedious modification is inevitable to their theranostic applications for the purpose of improving their stability and target therapy.<sup>12,18,20,21</sup> Additionally, the imaging units in these nanosystems are always the encapsulated contrast agents or fluorescein carried in an “always on” manner.<sup>17,22</sup> Hence, for precise diagnosis and efficient cancer therapy, it is of pioneering significance to develop an accessible and imageable nanomaterial for constructing a theranostic nanoplatform with a stimuli-triggered destruction mechanism.

Gold nanoclusters (AuNCs), known for their ultrasmall size and biocompatible properties, may offer an elegant solution to the need for simultaneously achieving stimuli-responsive contrast-enhanced imaging as a reporter, and maximizing the therapeutic efficacy and minimizing the side effect and toxicity as a nanovector.<sup>17,23,24</sup> As for a reporter, in the past few years, gold nanoclusters were mostly utilized for biosensing<sup>25</sup> and

State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, Hunan University, Key Laboratory for Bio-Nanotechnology and Molecule Engineering of Hunan Province, Changsha 410082, China. E-mail: xiaoxiaohe@hnu.edu.cn; kmwang@hnu.edu.cn

† Electronic supplementary information (ESI) available: Peptide and oligonucleotide sequences, specific cleavage activity of DNzyme, TEM images, zeta size and potential, stability investigation, real-time imaging of Dox release, cytotoxicity assays of MDA-MB-231 cells, etc. See DOI: 10.1039/d1sc03847h




bioimaging,<sup>26</sup> relying on their fluorescence emission properties.<sup>27,28</sup> Additionally, as a high-*z*-element based material, the AuNCs displayed strong absorption of radiation energy, and have been used as radiosensitizers in X-ray imaging and cancer radiotherapy.<sup>29,30</sup> Besides that, some other inherent superiorities of AuNCs have rarely been employed in the bioimaging process. Actually, the ultrasmall AuNCs exhibit significant energy-absorption capability to quench a fluorophore on its surface (<20 nm) through the interaction of the dipole-metal plane coupling, which was reported by the Strouse group and named nanosurface energy transfer (NSET) of AuNCs.<sup>31,32</sup> Based on this finding, AuNCs were synthesized to serve as an acceptor rather than a donor to design a nanosensor for stimuli-responsive contrast-enhanced imaging (the ratio of signal/noise was up to 20 *in vitro*) of caspase 3 activity in live cells.<sup>24</sup> The results displayed new potential of AuNCs which served as an activable reporter. More importantly, as for a nanocarrier, a simple synthetic route and multiple bio-ligands are available for AuNC synthesis,<sup>33,34</sup> such as SH-containing peptides,<sup>35,36</sup> proteins<sup>37</sup> and polymers.<sup>38</sup> They provide AuNCs with not only biocompatible shells and controllable surface charge to bind composite charged cargos to cross bio-barriers, but also multiple functional regions such as a tumor target domain and site-specific substrate to respond at a desired site by rational designing and regulating the proportion of ligands. It implies that AuNCs can also be engineered as multifunctional and biocompatible building blocks of nanocarriers synchronously when needed. For the combination of diagnosis and therapy based on AuNCs, although conceptually feasible, practically applying the NSET effect and ligand properties of AuNCs to achieve activable imaging, followed by controllable concentrated payload release *via* stimuli-detonated explosion has remained challenging until now.

To fulfill the stimuli-triggered on-demand cargo release in a detonation manner, the choice of stimulus is also a key factor. For the purpose of endowing the formulations with safe and

intelligent performance, an endogenous stimulus such as protease overexpressed and activated in some particular way could be considered in the design of the theranostic nanoplat-form on account of the exploitable relationship between the peptide ligand and substrate of protease. Legumain, a cysteine protease overexpressed in most human tumors, and particularly distributed in the lysosome,<sup>39</sup> is identified as a tumor marker, and has been largely utilized in the design of legumain-sensitive nanosensors or nanotheranostics for tumors.<sup>40–45</sup> The short peptides of alanine-alanine-asparagine (AAN), as a specific substrate of legumain, had a perfect attendance presented in different forms in these nanosystems. It inspired us that a fluorophore tagged AAN moiety could be incorporated with the peptide ligand to fabricate a turn-on legumain sensor with the aid of the NSET effect of AuNCs. The specific expression pattern of legumain lends itself not only to be an ideal stimulus for cancer cell imaging but also as an initiator for on-demand drug release.

Herein, we present the delicate design of stimuli-responsive nanotheranostics based on the multifunctional peptide-protected AuNCs, which acted as the activated nanosensor and cationic nanocarrier for legumain-triggered specific imaging and combinational therapy of cancer cells (Scheme 1). In this nanosystem, we synthesized multifunctional peptide-coated AuNCs by a one-step biomineralization method, where the peptides provided templates and reducing agent domain (CCY in P<sub>L1</sub>, P<sub>L2</sub> and P<sub>3</sub>), targeted domain (RGD in P<sub>L1</sub>, P<sub>L2</sub> and P<sub>3</sub>), positively charged domain (R<sub>9</sub> in P<sub>L1</sub>), legumain-specific substrate domain (AAN in P<sub>L1</sub>) and TAMRA labeled legumain-specific substrate domain (AAN-TAMRA in P<sub>L2</sub>), respectively. The fluorescence of TAMRA was absolutely quenched by the formed AuNCs through the NSET effect. The classic anticancer drug of Dox was inserted into the GC base pairs of functional nucleic acid DNAzyme-S (Dzs). Taking advantage of the positive charge on the AuNC surface, the negative therapeutic Dzs-DOX could be absorbed by AuNCs *via* electrostatic attraction to form



Scheme 1 Schematic illustration of nanocluster-bomb system (L-AuNCs/Dzs) synthesis and the detonation strategy for contrast enhanced cancer imaging and combination therapy.



large nanoparticles (AuNCs/Dzs-Dox). With the aid of the RGD peptide, AuNCs/Dzs-Dox nanoparticles preferentially target integrin  $\alpha_v\beta_3$  (a biomarker of various cancer cells) and enter into the cancer cells by receptor-mediated endocytosis. The fluorescence recovery and disaggregation of AuNCs/Dzs-Dox nanoparticles were successively triggered by the specific hydrolyzation of overexpressed legumain in the lysosome, achieving legumain-responsive imaging, specific cleavage of EGR-1 (regulates cancer cell proliferation) and Dox release for combinational therapy of cancer cells definitively. The compatibility and the use of AuNCs/Dzs for activated fluorescence imaging, combination therapy of cancer cells *in vitro* and a tumor model *in vivo* were systematically tested.

## Results and discussion

### Synthesis, characterization and optimization of trypsin-responsive AuNCs (T-AuNCs)

In order to facilitate the investigation of feasibilities of this work, trypsin was used as the model enzyme at the beginning of the work (for pretest). The peptide-functionalized AuNCs were synthesized by one-step reduction of  $\text{Au}^{3+}$  according to a previous study.<sup>31</sup> In our synthesis system, three kinds of peptides, positive peptide  $P_{T1}$  (CCYRRRRRRRRRGD), signal peptide  $P_{T2}$  (CCYGGGGGRGK (TRMRA) RGD) and helper peptide  $P_3$  (CCYGGGGGRGKRGD) with multifunctional domains were utilized to form the trypsin-responsive AuNCs (T-AuNCs). In detail, all three of the peptides were sharing the same functional domains: (1) ligand domain CCY, in which tyrosine (Y) provides phenolic groups as the reducing agent for the reduction of  $\text{Au}^{3+}$  under alkaline conditions and cysteine (C) provides -SH as the anchoring site for Au atom clustering *via* the Au-S bond; (2) targeted domain RGD which has high-affinity to integrin  $\alpha_v\beta_3$  which is overexpressed in breast, lung and pancreatic cancer cells.<sup>46</sup> Besides,  $P_{T1}$  contains an oligoarginine segment (R8: eight arginine residues) which bears a positive charge to serve as a cationic carrier for nucleic acid delivery;  $P_{T2}$  contains a trypsin specific substrate labeled with a fluorophore tag, and is utilized as a signal unit for trypsin activity detection;  $P_3$  acts as a helper peptide to synthesize AuNCs so as to enhance the fluorescence signal-to-noise (S/N) ratio of enzyme activity assay.

To obtain the T-AuNCs with a higher S/N ratio of trypsin cleavage, the fluorescence emission spectra of T-AuNCs synthesized in different molar ratios of  $P_{T1}$ ,  $P_3$  (non-fluorescence peptides were collectively named  $P_0$ ) and  $P_{T2}$  were investigated separately, and the fluorescence S/N ratios of their products in response to trypsin cleavage were calculated (Table S2†). We also tested the fluorescence stability of T-AuNCs in a month, and the ratio of  $P_0 : P_{T2}$  at 30 : 1 and 60 : 1 showed better quality and a higher S/N ratio (data not shown). Then T-AuNCs synthesized with different concentrations of NaOH in the peptide ratio of  $P_0 : P_{T2}$  at 30 : 1 and 60 : 1 were obtained and the corresponding S/N ratio was evaluated (Table S3†). The results demonstrated that a crucial control of pH of the reaction system was necessary for the synthesis of AuNCs due to the isoelectric point around 10–12 of the peptides, as

well as demand for proper alkaline conditions for reduction. Therefore, we finally decided to use  $P_{T1}$ ,  $P_3$ , and  $P_{T2}$  at a molar ratio of 30 : 30 : 1 and the concentration of NaOH at 0.5 M to synthesize T-AuNCs. The fluorescence spectra of the optimal T-AuNCs ( $P_{T2}$ -TAMRA) and their trypsin-responsive performance (cleaved  $P_{T2}$ -TAMRA) are illustrated in Fig. 1A, where the S/N ratio was calculated to be about 20. We then tested the optical properties of the as-prepared T-AuNCs. It was demonstrated that there were broad absorption bands from 200 nm to 700 nm with two shoulder peaks at 242 nm and 294 nm derived from the phenoxide structure of tyrosine (Fig. 1B), which was consistent with those previously reported.<sup>47</sup> As shown in Fig. 1C and Fig. A, it was demonstrated that T-AuNCs exhibited almost no fluorescence but only strong quenching ability to TAMRA due to the NSET effect. For the morphology characterization, a typical TEM image showed that the obtained T-AuNCs were well-dispersed with an average size around 1.76 nm (Fig. 1D). As expected, the T-AuNCs had a positive surface charge of 26.6 mV owing to the oligoarginine segments on the peptides (Fig. 1E), which endowed themselves with the potential of acting as a cationic carrier to deliver negative therapeutic cargos (drug loaded nucleic acids). The stability test of T-AuNCs revealed that the S/N ratio remains almost unchanged upon keeping at 4 °C for a month




Fig. 1 (A) Normalized fluorescence spectra of T-AuNCs ( $P_{T2}$ -TAMRA) synthesized in the ratio of  $P_{T1}$ ,  $P_3$ , and  $P_{T2}$  at 30 : 30 : 1 and their fluorescence recovery (cleaved  $P_{T2}$ -TAMRA) response in the presence of trypsin. (B) Absorption spectra, (C) excitation and emission fluorescence spectra, (D) TEM image (scale bar: 10 nm, insert: size distribution), and (E) zeta potential of T-AuNCs. (F) Response of T-AuNCs to trypsin after storage for various weeks.



(Fig. 1F). All of these results suggested that the peptide-coated AuNCs were successfully obtained with expected properties such as stimuli-responsiveness, high NSET efficiency and positive charge, showing the potential of AuNCs to act as a high contrast reporter and a nanocarrier.

### Specific cleavage ability and drug loading capacity of Dz

To construct a theranostic nanoplatform, a segment of EGR-1 specific DNAzyme and a CG-rich region were ligated to serve as a part of the negative therapeutic unit. The former region was a typical 10–23 DNAzyme for gene therapy *via* specific cleavage of mRNA in the presence of  $Mg^{2+}$ <sup>48</sup> while another  $S_4$  complementary to the latter region was introduced to form partially double-stranded DNA with  $Dz_4$  for Dox loading, finally to be engineered as the whole negative therapeutic unit. 12% native polyacrylamide gel electrophoresis (PAGE) was used for determining the feasibility of DNAzyme specific cleavage of EGR-1 and strand assembly. As shown in Fig. S1A,†  $Mg^{2+}$  could trigger DNAzyme to completely cleave  $S_1$  but had no effect on  $S_2$  (no rArU site) within 2 h, while neither the single base mutant DNAzyme nor the typical 10–23 DNAzyme without the cofactor showed catalytic activity. Then we found that the assembly of three major nucleic acid strands ( $Dz$ ,  $S_5$  (prolonged  $S_4$ ), and  $S_2$ ) and the specific cleavage of  $S_2$  of the assembly with the aid of  $Mg^{2+}$  were also feasible (Fig. S1B†). These results demonstrated that the Dz endowed it with the specific cleavage ability of target mRNA. We then explored the drug loading capacity of Dz. As illustrated in Fig. S2A,† the fluorescence intensity of Dox was gradually decreased with the increased concentration of Dz, which saturated at a concentration of 370 nM ( $Dz/Dox = 0.37$ ), indicating the successful drug loading of Dz.<sup>49</sup>

### Aggregation and disaggregation of T-AuNCs and Dz

We further explored the potential of the T-AuNCs as a nanovector for gene delivery. The as obtained T-AuNCs were embedded with abundant positive charges because of the oligoarginine segments of the peptides at a physiological pH value ( $pH < pI$ ). In general, cationic T-AuNCs can effectively absorb negative therapeutic cargos to form larger nanoparticles *via* electrostatic attraction. Hence, the TEM images were recorded and shown in Fig. 2B, which revealed that a large amount of nanoparticles was formed with a diameter of  $17.8 \pm 5.0$  nm. We further confirmed the binding of Dz to T-AuNCs by comparing the differences in the element composition with EDS spectra in Fig. 2C and S3.† Owing to the involvement of Dz, the aggregates exhibit substantial surface P element, which absolutely comes from the phosphate of nucleotides. Gel electrophoresis was also performed, as illustrated in Fig. S4,† and there was an obvious trend where the free Dz band gradually got weak with the increased concentration of T-AuNCs till the molar ratio of Dz/T-AuNCs decreased to 0.004. These results demonstrated that Dz had successfully been absorbed by the positive T-AuNCs.

The primary design of AuNCs/Dzs nanoparticles is that the aggregated nanoparticles would be responsively activated and disaggregated for imaging and therapy by the overexpressed




Fig. 2 (A) Schematic illustration of trypsin triggered disaggregation of T-AuNCs/Dzs-FAM. (B) TEM image of T-AuNCs + Dz (scale bar: 50 nm). (C) EDS spectra of T-AuNCs + Dz. (D) TEM image of T-AuNCs + Dz + trypsin (scale bar: 20 nm). (E) The fluorescence spectra of (a) Dz-FAM, (b) T-AuNCs + Dz-FAM, (c) T-AuNCs + Dz-FAM + trypsin (FAM), (d) T-AuNCs, (e) T-AuNCs + trypsin, and (f) T-AuNCs + Dz-FAM + trypsin (TAMRA).

protease in the cancer cells. As a consequence, we further explored the activation and disaggregation feasibility of T-AuNCs/Dzs nanoparticles in the presence of a model enzyme. As shown in Fig. 2D, the TEM image showed that the particle size was decreased to  $2.98 \pm 0.5$  nm after incubating T-AuNCs/Dzs with trypsin in PBS for 1 h, implying that Dz had almost fallen off from T-AuNCs. Moreover, the NSET effect of AuNCs inspired us to verify the detachment of T-AuNCs and Dz by monitoring the fluorescence intensity change of FAM labeled Dz (Dzs-FAM) in the reaction system with or without the addition of trypsin. As expected, the T-AuNCs showed almost absolute quenching of Dz-FAM upon the formation of aggregates, while the quenched Dz-FAM could be greatly recovered with the aid of trypsin cleavage, accompanied by the fluorescence restoration of T-AuNCs (Fig. 2E). These data clearly suggested that the T-AuNCs/Dzs nanoparticles have the potential to be a protease-responsive nanoplatform for precise imaging and therapy of cancer cells by merely changing the sequence of substrate peptides.

### Preparation of legumain-responsive AuNCs (L-AuNCs) and *in vitro* response of L-AuNCs

After verifying the T-AuNC based aggregation–disaggregation feasibility with the aid of the model enzyme, we synthesized legumain-specific AuNCs (L-AuNCs) and used them as a cationic carrier to absorb the negative therapeutic agent of Dz. Herein, positive peptide  $P_{L1}$  (CCYAANRRRRRRRRGD),






Fig. 3 (A) Normalized fluorescence spectra of legumain-responsive AuNCs synthesized in the ratio of  $P_{L1}$ ,  $P_3$ , and  $P_{L2}$  at 30 : 30 : 1. (B) Fluorescence stability of L-AuNCs in 5 weeks. (C) Selectivity of L-AuNCs against various ions or proteins. (D) 8% PAGE analysis of aggregation between L-AuNCs and Dzs with different ratios.

signal peptide  $P_{L2}$  (CCYGGGGAANRK(TRMRA)RRGD) and helper peptide  $P_3$  (CCYGGGGRGRKRGD) with a molar ratio of  $P_{L1}/P_3/P_{L2}$  at 30 : 30 : 1 were utilized to prepare L-AuNCs. Compared to the ligands of T-AuNCs, a specific recognition site (AAN) of legumain was inserted into the positive peptide and signal peptide of L-AuNCs for the purpose of accelerating the detonation process. The fluorescence response of L-AuNCs to legumain was tested and the S/N ratio was calculated subsequently (Fig. 3A). As anticipated, the L-AuNCs retained the fluorescence off state due to the highly efficient NSET from TAMRA to the AuNC surface, whereas the addition of legumain significantly increased the fluorescence signal by  $\sim 12$ -fold, suggesting that the legumain specifically hydrolyzed the substrate peptide of  $P_{L2}$  and markedly released TAMRA from L-AuNCs. The stability and selectivity of L-AuNCs were also examined, as shown in Fig. 3B and C, and the favorable results indicated that the L-AuNCs were definitely fit to be applied in the complex intracellular matrix.

### Aggregation and characterization of L-AuNCs/Dzs nanoparticles

Afterwards, the ability of L-AuNCs to bind DNA was displayed by PAGE. Fig. 3D shows that no free Dzs band could be observed when the molar ratio of Dzs/T-AuNCs decreased to 0.0033, which was chosen as the final ratio for the following experiments. Following the exploratory steps of T-AuNCs, the morphology and zeta potential of pure L-AuNCs and L-AuNCs/Dzs were also obtained (Fig. S5A–C<sup>†</sup>). The results showed that L-AuNCs were well-dispersed with an average size around 1.81 nm and positive surface charge of 20 mV, while L-AuNCs/Dzs exhibited a nearly neutral potential. The TEM image results of legumain responsive disaggregation of L-AuNCs/Dzs

nanoparticles were tested as Fig. S5D,<sup>†</sup> which was consistent with the results the model enzyme.

We then investigated the biological stability of L-AuNCs/Dzs nanoparticles by treating them with FBS and DNase I. PAGE analysis (Fig. S6A<sup>†</sup>) revealed that the L-AuNCs/Dzs nanoparticles treated with 10% FBS still maintained their integrity without releasing Dzs for 40 h. Besides, DNase I ( $1.5 \text{ U mL}^{-1}$ ) was utilized to treat free  $Dz_4$ -Bhq1- $S_4$ -FAM and L-AuNCs/Dzs-FAM, respectively. By monitoring the fluorescence recovery of FAM digested from each of them, it was found that L-AuNCs/Dzs-FAM nanoparticles showed negligible fluorescence recovery compared to free Dzs after incubating with DNase I for 1.4 h ( $1.5 \text{ U mL}^{-1}$ ) (Fig. S6B<sup>†</sup>). To simulate the biological environment *in vivo*, 100% FBS was used to test the stability of these nanoparticles by fluorescence analysis (Fig. S6C<sup>†</sup>). The results demonstrated the excellent stability of the formed L-AuNCs/Dzs nanoparticles.

### Targeted cellular uptake and *in situ* activation of L-AuNCs/Dzs for specific cell imaging

In order to investigate the targeted cellular uptake and *in situ* activation of L-AuNCs/Dzs for specific cell imaging, Dzs absorbed by the L-AuNCs was labeled with FAM. As we known, TAMRA of L-AuNCs and Dzs-FAM was absolutely quenched by L-AuNCs in the L-AuNCs/Dzs-FAM nanoparticles. First, we monitored the time-dependent cellular internalization of L-AuNCs/Dzs-FAM. The confocal laser scanning microscopy (CLSM) images of MDA-MB-231 cells were recorded after various incubation time-intervals. As shown in Fig. 4A and B, only weak fluorescence could be observed on the cell membranes after 1 h, which might result from the traces of legumain's contribution distributed on the cell surface. Then, the fluorescence intensity of TAMRA and Dzs-FAM in the cells was gradually enhanced with prolonged incubation time till 4 h, indicating the large cleavage of TAMRA labeled substrate peptides by overexpressed legumain and the complete release of Dzs-FAM. As shown in Fig. 4C, by analyzing the co-localization fluorescence, the signal activated by legumain was mainly observed in the lysosome at first and then distributed around the cell, which was consistent with the literature.<sup>34</sup> Moreover, as depicted in Fig. S7,<sup>†</sup> L-AuNCs also served as a control probe to compare the cellular uptake efficiency. The results showed that the internalization efficiency of aggregated AuNCs was significantly enhanced compared to that of the free AuNCs, and thus largely enhanced the imaging contrast. To further demonstrate the specificity of legumain-activated cell imaging, the fluorescence images were tested by CLSM in breast cancer cells (MCF-7 and MDA-MB-231) and normal cells (MCF-10A and L02). As shown in Fig. 4D, the normal cells showed negligible fluorescence recovery after incubation with L-AuNCs/Dzs-FAM for 4 h, while the cancer cells MDA-MB-231 exhibited stronger fluorescence intensity than MCF-7 and much higher than normal cells for their different legumain concentrations and integrin  $\alpha_v\beta_3$  expression levels.<sup>34</sup> The control probe of T-AuNCs/Dzs was also utilized to test the specificity of nanoparticle disaggregation, as shown in Fig. S7.<sup>†</sup> Due to the lack of specific substrates of legumain, the






Fig. 4 (A) Time-dependent cell penetration process of L-AuNCs/Dzs characterized by CLSM. (B) Average fluorescence intensity analysis of time-dependent cellular uptake images. (C) Magnified picture of colocalization analysis of lysosomes after cells were incubated with L-AuNCs for 4 h and lysosome tracker for 10 min. (D) CLSM images of MCF-10A cells (column 1), L02 cells (column 2), MCF-7 cells (column 3) and MDA-MB-231 cells (column 4) treated with L-AuNCs/Dzs for 4 h.

MDA-MB-231 cells treated T-AuNCs/Dzs showed nearly no fluorescence recovery. The above results demonstrated that the aggregation–disaggregation behavior of L-AuNCs/Dzs triggered by legumain significantly improved the imaging contrast due to the activable mechanism and enhanced cellular uptake of AuNCs. In addition, these endogenous stimuli of legumain also specifically initiated the concentrated release of Dzs from the nanoparticles.

### Investigation of Dox loading and release

To verify the Dox loading capacity of L-AuNCs/Dzs nanoparticles, UV-vis spectra of L-AuNCs (black line), Dzs (red line), Dox (green line), AuNCs + Dzs (yellow line), Dox + Dzs (blue line) and L-AuNCs + Dox + Dzs (purple line) were recorded, as shown in Fig. S2B.† The L-AuNCs showed broad absorption bands from 200 nm to 700 nm with two shoulder peaks at 242 nm and 294 nm, which were consistent with those of T-AuNCs. Dzs exhibited a characteristic peak at 260 nm for purine and pyrimidine bases of DNA; however the peak was apparently weakened and the absorption value in the range of 200 nm to

700 nm showed a general upward after the introduction of L-AuNCs, indicating the aggregation of L-AuNCs and Dzs. Dox showed a typical absorption centered at 480 nm, whereas the peak disappeared upon the addition of Dzs, suggesting a perfect intercalation of Dox into double-stranded GC pairs. Finally, the mixture of L-AuNCs, Dox and Dzs demonstrated stronger absorption signals between 200 nm and 700 nm with the absence of peaks at 480 nm and 260 nm corresponding to free Dox and Dzs respectively, indicating a complete loading of Dox by L-AuNCs/Dzs nanoparticles with a molar ratio of Dzs/Dox/L-AuNCs at 1 : 2.7 : 300, which was selected as the final ratio for the following experiments. To study the legumain-triggered intracellular drug release of L-AuNCs/Dzs-Dox, the fluorescence change of Dox in the MDA-MB-231 cells were monitored by CLSM. After a 4 hour incubation of MDA-MB-231 cells and L-AuNCs/Dzs-Dox, an increasing red fluorescence was detected in the cell cytoplasm and finally in the nucleus (Fig. S8†).

### Cell cytotoxicity evaluation of L-AuNCs/Dzs-Dox nanoparticles

For the purpose of evaluating the cell killing ability of L-AuNCs/Dzs-Dox nanoparticles, the biocompatibility of the delivery system was first tested by using L-AuNCs/mDzs, in which the mutant DNzyme was introduced to rule out the possibility of gene therapy. In the range of 0–300 nM, L-AuNCs/mDzs exhibited high biocompatibility (Fig. S9†). Afterwards, we further studied the mono-therapy of gene and drug, respectively, in this range. Once L-AuNCs/Dzs was internalized into the cells, the disaggregation triggered by over-expressed legumain could also initiate the cargo release of Dzs. To investigate their cell cytotoxicity, various concentrations of L-AuNCs/Dzs were used to treat MDA-MB-231 cells, as shown in Fig. S10A,† whose cell viability showed a concentration-dependent feature. To further explore the cytotoxicity mechanism, a mutant DNzyme (mDz) was introduced as the control by substituting one nucleotide of the DNzyme catalytic core with no effect on its binding affinity. The results showed that the expression level of EGR-1 was apparently down-regulated merely in L-AuNCs/Dzs-treated MDA-MB-231 cells, as shown by qRT-PCR (Fig. 5A) and western blot analysis (Fig. 5B). These data indicated that the detonation strategy based on legumain-triggered disaggregation of AuNCs/Dzs was an effective strategy for the DNzyme-mediated suppression of EGR-1 of cancer cells.

Subsequently, L-AuNCs/mDzs nanoparticles were utilized to load Dox for evaluating chemotherapeutic efficacy. As displayed in Fig. S10B,† the cell viability of MDA-MB-231 cells showed a downward trend in a “fast followed by slow” manner with the increased concentration of L-AuNCs/mDzs-Dox.

Finally, the combinational gene-chemo cancer therapeutic efficacy was studied against MDA-MB-231 and L02 cell lines at a concentration of 200 nM by MTS assay (Fig. 5C). Compared to negligible therapeutic efficacy of free Dzs (0.00%), mono-treatment of L-AuNCs/Dzs ( $18.2 \pm 1.5\%$ ) L-AuNCs/mDzs-Dox and AuNCs/mDzs-Dox ( $54.1 \pm 0.1\%$ ), gene-chemo combinational treatment using L-AuNCs/Dzs-Dox ( $71.4 \pm 0.4\%$ ) obviously exhibited expressively higher therapeutic efficiency to MDA-MB-231 cells in 48 h. In contrast, the distribution of L02 cells treated






Fig. 5 Cell apoptosis assays and gene silencing. (A) QRT-PCR analysis of EGR-1 and GAPDH. (B) Western blot analysis of EGR-1. (C) Therapeutic efficacy evaluation of MDA-MB-231 and L02 cells by MTS assay. (D) FITC-annexin V and propidium iodide (PI) stained cell apoptosis assay via flow cytometry. The results are presented as the mean standard deviation (SD) (\* $p < 0.05$ , \*\*\* $p < 0.001$ ).

with varying samples showed a slight distinction due to the low-level of pivotal integrin and legumain. Free Dox presented a similar toxicity to both cell lines due to the lack of selectivity. To further assess the ability of L-AuNCs/Dzs-Dox to trigger tumor cell apoptosis, as shown in Fig. 5D, annexin V-FITC/PI assay by flow cytometry was adopted to analyze the cell viability. As expected, the cell apoptosis percentages of each group were in good accordance and showed an acceptable difference with MTS assays because of distinct postprocessing and instruments. Taken together, these results revealed that AuNC-based stimulus-responsive nanoplateforms are highly efficient for chemo/gene therapy of cancer cells.

#### *In vivo* specific response to L-AuNCs/Dzs-Cy7


To further explore the feasibility of our L-AuNCs/Dzs system for a more challenging *in vivo* imaging, the Cy7 labelled L-AuNCs/Dzs system was injected into MDA-MB-231 tumor-bearing mice. The fluorescence of Cy7 of the L-AuNCs/Dzs system was enhanced gradually and reached the maximum value at 2 h and sustained for 8 h at the tumor site after injection (Fig. 6A). To identify the specific response of tumor to the L-AuNCs/Dzs system, T-AuNCs/Dzs, without the legumain specific substrate, was set as another group and the average fluorescence intensity of both groups (L-AuNCs/Dzs-Cy7 and T-AuNCs/Dzs-Cy7) was calculated. As presented in Fig. 6B, the L-AuNCs/Dzs-treated mice displayed 2.7-fold higher intratumoral fluorescence than that treated with the T-

AuNCs/Dzs system. Additionally, the fluorescence intensity at the tumor site was found to be about 4-fold higher than that of the normal site in the group of L-AuNCs/Dzs. Therefore, accurate tumor-imaging was achieved in living mice by using the L-AuNCs/Dzs platform.

#### *In vivo* antitumor efficacy of L-AuNCs/Dzs-Dox

To evaluate the antitumor activities of L-AuNCs/Dzs-Dox, five treatment groups of PBS, L-AuNCs/mDzs, L-AuNCs/Dzs, L-AuNCs/mDzs-Dox and L-AuNCs/Dzs-Dox were intratumorally injected into MDA-MB-231 tumor-bearing mice with an average tumor volume of about 100 mm<sup>3</sup>. As depicted by the tumor growth curves in Fig. 6C, compared with gene therapy or chemotherapy alone, the combined therapy could significantly suppress tumor growth, demonstrating an improved antitumor treatment. Meanwhile, the safety of this nanocarrier was demonstrated by the general slightly increased body weight observed for most mice and the tumor growth variation of group L-AuNCs/mDzs (Fig. 6D). The therapeutic effect was further illustrated by the photographs of tumors harvested at day 20 post-injection (Fig. 6E), indicating the greatest potency of L-AuNCs/Dzs-Dox for tumor growth inhibition. Hematoxylin-Eosin (H&E) staining revealed the severe structural deformation and more apoptotic cells in the L-AuNCs/Dzs-Dox group, demonstrating the higher antitumor capability of the present chemo/gene therapy (Fig. 6F). These results demonstrated that the multifunctional AuNC-based stimulus-responsive





**Fig. 6** (A) Real-time fluorescence images of mice before and after intratumoral injection of L-AuNCs/Dzs-Cy7 and T-AuNCs/Dzs-Cy7 for 0.5 h, 1 h, 2 h, 4 h and 8 h. (B) Quantification of the fluorescence intensity corresponding to (A) at different times. (C) Tumor growth profiles and (D) body weight of mice under different treatments for 20 days. (E) Photographs of the tumors surgically dissected from the tumor-bearing mice in the five treatment groups. (F) H&E staining analysis results of tumors in (E) administered with different treatments. In (B) and (C), the values of the fluorescence intensity and tumor volume represent the mean calculated from at least 3 mice and the error bars indicate the SD from the mean. \*, \*\* and \*\*\* indicate  $P < 0.05$ ,  $P < 0.01$  and  $P < 0.001$ , respectively.

nanoplatfrom has the potential to be applied for clinical applications as a therapeutic platform to treat cancer *in vivo*.

## Conclusions

In summary, we have successfully constructed a multifunctional gold nanocluster-based bomb as a potent and precise co-delivery nanosystem for stimulus-responsive imaging and efficient combination cancer therapy. By utilizing the AuNCs as building blocks of both nanocarrier and reporter, this fabricated nanocluster-bomb demonstrated the following advantages: (1) the endogenous stimuli of legumain were introduced to hydrolyze the bioligand of AuNCs, endowing this nanocluster-bomb system with safe and intelligent performance; (2) based on the highly NSET effect of multifunctional AuNCs and their aggregation–disaggregation mechanism, the targeted cellular uptake efficiency was obviously improved and led to contrast-enhanced cancer imaging; (3) the mechanism of AuNC-based aggregation–disaggregation triggered by legumain not only enriched the payload species, but also realized on-demand and concentrated cargo release. Collectively, the *in vitro* and *in vivo* studies revealed that the detonation strategy based on AuNCs/Dzs-Dox readily achieved contrast-enhanced cancer imaging and efficient gene/chemo combination therapy. To our knowledge, this is the first time to report the application of relying on AuNCs' NSET-dependent quenching effect and detonation mechanism for stimulus-responsive cancer imaging

and gene/chemo therapy. By replacing the peptide substrate or DNA sequence, the multifunctional AuNCs/Dzs can serve as a versatile platform and can be widely explored for probing complex enzymatic profiles and gene targets, thus achieving precise and efficient cancer theranostics.

## Experimental

### Chemicals and materials

All the peptides used in the experiments were chemically synthesized and purified by a solid phase method from Guoping Pharmaceutical (Hefei, China). The basic information of the synthesized peptides is given in Table S1.† All the oligonucleotides used in this study were synthesized by Sangon Biotechnology (Shanghai, China). Before use, all the oligonucleotides were purified with high performance liquid chromatography (HPLC) and further identified using mass spectrometry. The sequences of oligonucleotides are listed in Table S4.†

Hydrogen tetrachloroaurate tetrahydrate ( $\text{HAuCl}_4 \cdot 4\text{H}_2\text{O}$ , >99%), sodium hydroxide (NaOH), sodium chloride (NaCl), magnesium chloride ( $\text{MgCl}_2$ ), and potassium chloride (KCl) were obtained from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China). Trypsin was purchased from Sigma-Aldrich (St. Louis, MO). Recombinant human legumain protein (Pro form, 10  $\mu\text{g}$ , specific activity  $>250 \text{ pmol min}^{-1} \mu\text{g}^{-1}$ ) was purchased from R & D Systems (Minneapolis, MN). Tris-(2-carboxyethyl) phosphine (TCEP) was purchased from Meilun



Biotech (Dalian, China). All other reagents and solvents were of analytical grade and used without further purification. All solutions were prepared using deionized water, obtained from a Milli-Q ultrapure water system ( $>18.2$  M $\Omega$  cm resistivity, Billerica, MA).

### Synthesis of AuNCs

Synthesis and purification of peptide-capped AuNCs was carried out following the published procedures with appropriate modifications.<sup>31</sup> Trypsin was used as a model enzyme in this work for the pretest. We varied the ratio of the positive peptide ( $P_{T1}$ ), signal peptide ( $P_{T2}$ ) and helper peptide ( $P_3$ ) in the AuNC synthesis to incorporate functional groups on the AuNCs surface. Briefly, freshly prepared aqueous solution of HAuCl<sub>4</sub> (16  $\mu$ L, 25 mM) was slowly added to 376  $\mu$ L of aqueous solution of peptides (total final concentration: 1 mM) in an Eppendorf tube with vigorous stirring. Then around 8  $\mu$ L of 0.5 M NaOH was slowly added to adjust the pH of the solution to about 10. Then the sample was stored and sealed for 13 h at 37 °C undisturbed in the dark to produce the trypsin-responsive AuNCs (T-AuNCs). The obtained T-AuNC solution (400  $\mu$ L) was concentrated and washed with ultrapure water five times through ultrafiltration using a centrifugal filter unit (Amicon Ultra-0.5 mL, MWCO 10 kDa) so as to remove the unbound peptide and redundant HAuCl<sub>4</sub>. The concentrated AuNCs were resuspended in deionized water and diluted to 400  $\mu$ L (1 mM based on the AuNC particle concentration). The synthesis procedure and final optimal peptide ratio were also used to prepare the L-AuNCs (legumain responsive AuNCs) with corresponding functional peptides ( $P_{L1}$ ,  $P_{L2}$  and  $P_3$ ).

### NSET investigation of T-AuNCs

T-AuNCs (1  $\mu$ L, 1 mM) and trypsin (1  $\mu$ L, 500 U) were introduced into PBS (pH = 7.4, 10 mM) with a total volume of 200  $\mu$ L. By recording and calculating the fluorescence intensity of T-AuNCs (Noise) and trypsin treated T-AuNCs (Signal) on a PTI QuantaMaster™ 4 (Birmingham, UK) fluorescence spectrophotometer, NSET efficiency ( $S/N$ ) could be obtained.

### Gel electrophoresis analysis

12% polyacrylamide gel (PAGE) was employed to test the cleavage activity of 10–23 DNazyme (DZ) and functional nucleic acid (Dzs) assembly feasibility (Dz<sub>4</sub>-S<sub>4</sub>). All samples were prepared in Tris-HCl buffer (pH 7.5, 150 mM NaCl) with a final concentration of nucleic acids at 1  $\mu$ M and Mg<sup>2+</sup> at 15 mM. The electrophoresis analysis was conducted at 100 V for 2 h and recorded by using an Azure C600 Imaging Biosystems (California, USA). Electrophoretic mobility shift assay with 8% PAGE was used to evaluate the aggregation of AuNCs and Dzs.

### Preparation and characterization of AuNCs/Dzs nanoparticles

To simulate the physiological environment, phosphate buffered solution (PBS, pH = 7.4, 10 mM) was used to assemble the positive AuNCs and negative nucleic acids. For morphology characterization, the AuNCs/Dzs was aggregated in Tris-HCl

(pH = 7.4) and examined by transmission electron microscopy (TEM, Tecnai G2 F20 S-TWIN). The surface charge of the prepared nanomaterials was determined using dynamic light scattering (NanoZS, Malvern).

### Specific legumain responsiveness of L-AuNCs

To determine the specific legumain-responsiveness of L-AuNCs, a hydrolysis assay was used for the evaluation. In a typical activation procedure, pro-legumain protease was diluted in the activation buffer (pH = 4.0, 50 mM CH<sub>3</sub>CO<sub>2</sub>Na, and 100 mM NaCl) and incubated at 37 °C for 2 h. Then, the activated legumain was diluted to 10  $\mu$ g mL<sup>-1</sup> and reacted with 5 mM L-AuNCs in the assay buffer (pH = 5.0, 50 mM MES, and 250 mM NaCl) at a total volume of 200  $\mu$ L. Under the same conditions, various reactants including Na<sup>+</sup> (150 mM), K<sup>+</sup> (5 mM), Mg<sup>2+</sup> (15 mM), glucose (10 mM), glutamine (1 mM), hemoglobin (200 nM), lysozyme (200 nM), BSA (1 mM) and GSH (5 mM) were used to test the selectivity of L-AuNCs.

### Studies of stability and digestion resistant ability of L-AuNCs/Dzs

To validate the stability and anti-inference ability of the L-AuNC-based nanocarrier system, 8% PAGE was performed after L-AuNCs/Dzs was incubated in 10% FBS at 37 °C for different times. Digestion resistant ability of L-AuNCs/Dzs was also investigated by comparing the fluorescence spectra of Dz<sub>4</sub>-Bhq1-S<sub>4</sub>-FAM and L-AuNCs/Dz-S<sub>4</sub>-FAM after being treated with DNase I. The fluorescence intensity of L-AuNCs/Dzs-FAM, Dzs-FAM, L-AuNCs and L-AuNCs/Dzs-FAM + legumain was monitored after being incubated with 100% FBS for 120 min.

### Cell culture

MDA-MB-231 cells (human breast carcinoma) and MCF-7 cells (human breast carcinoma) were obtained from the cell bank of Central Laboratory at Xiangya Hospital (Changsha, China), and cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (obtained from Invitrogen) and 100 IU mL<sup>-1</sup> penicillin-streptomycin. L02 cells (normal human hepatic cell line) were cultured in 1640 medium and MCF-10A cells (normal human mammary epithelial cell line) were grown in DMEM/F12 medium (Procell Life Science & Technology Co., Ltd.) supplemented with 5% HS, 20 ng mL<sup>-1</sup> EGF, 10  $\mu$ g mL<sup>-1</sup> insulin, 0.5  $\mu$ g mL<sup>-1</sup> hydrocortisone, 1% NEAA, and 1% P/S solution. All cells were maintained in a 5% CO<sub>2</sub> humidified incubator at 37 °C.

### Confocal laser scanning microscopy (CLSM) experiments

All cells were seeded on 35 mm glass bottom dishes and maintained for 36 h. Afterwards, the medium in the dishes was removed and cells were washed twice with phosphate buffered saline (PBS, pH 7.40, Ca<sup>2+</sup> and Mg<sup>2+</sup> free). For the time-dependent cellular uptake of L-AuNCs/Dzs and co-localization of lysosomes, L-AuNCs/Dzs-FAM (15  $\mu$ M : 50 nM) resuspended in PBS (5% FBS) was used to incubate with MDA-MB-231 cells for imaging at different points in time. The cells were introduced



with a lysosome tracker for 10 min and washed 3 times with PBS before imaging. For the specific cell imaging investigation, L-AuNCs/Dzs-FAM (22.5  $\mu\text{M}$  : 75 nM) resuspended in PBS (5% FBS) was used to treat the four kinds of cells separately for 4 h. The lasers and emission filters were described as follows. Lysosome tracker/hoechst 33 342: Ex = 405 nm, Em = 425–475 nm, FAM: Ex = 488 nm, Em = 500–550 nm, TAMRA: Ex = 561 nm, and Em = 570–620 nm.

### Dox loading and release investigation

Dox solution (1  $\mu\text{M}$ ) was incubated with various concentrations of Dzs at room temperature for 30 min. Then the drug loading capacity of Dzs was quantified by recording the fluorescence of Dox with a PTI QuantaMaster™ 4 fluorescence spectrophotometer. A UV-vis spectrophotometer was used for the quantification of drug loading capacity of L-AuNCs/Dzs and for the purpose of ensuring the absolute absorption of Dzs by L-AuNCs simultaneously. To determine the legumain triggered Dox release behavior of MDA-MB-231 cells, 2 h, 3 h, 4 h and 5 h were set to monitor the fluorescence of Dox, respectively. Dox: Ex = 488 nm and Em = 570–620 nm.

### Cytotoxicity assays

The cell viability was determined using Cell Titer 96 cell proliferation assay. Briefly, cells ( $4 \times 10^4$  cells per well) were treated with different probes suspended in PBS (37 °C, 5% CO<sub>2</sub>) for 4 h, respectively. Then, the solution was removed and replenished with fresh medium (10% FBS) for further cell growth (48 h). Subsequently, the MTS reagent (20  $\mu\text{L}$ ) and fresh culture medium (100  $\mu\text{L}$ ) were added to each well and incubated for 1–2 h at 37 °C after removal of the old medium. The absorbance (490 nm) was recorded using a Bio-RAD (Benchmark, USA). Cell viability was calculated as described by the manufacturer.

### Quantitative reverse polymerase chain reaction (qRT-PCR) analysis of EGR-1

To quantify the relative expression of EGR-1 in MDA-MB-231 cells, the cells with different treatments were prepared for qRT-PCR. Total cellular RNA was extracted from the cells using TRIzol reagent following the manufacturer's instructions. Afterward, the products were stored at –80 °C for the qRT-PCR analysis (Sangon Co. Ltd., Shanghai, China). The sequences of PCR primers are listed as follows.

EGR-1 forward primer: 5'-TGACCGCAGAGTCTTTTCCT-3'

EGR-1 reverse primer: 5'-TGGGTTGGTCATGCTCACTA-3'

GAPDH forward primer: 5'-TGGGTGTGAACCATGAGAAGT-3'

GAPDH reverse primer: 5'-TGAGTCCTTCCACGATACCAA-3'

### Western blot analysis of EGR-1

MDA-MB-231 cells were treated with PBS, Dzs, L-AuNCs/mDzs, and L-AuNCs/Dzs for 4 h, respectively. Afterward, the solution was removed and replenished with fresh medium (10% FBS) for further cell growth (48 h). MDA-MB-231 cells were washed with PBS (10 mM, pH = 7.4) and then 100  $\mu\text{L}$  of RIPA lysis buffer

supplemented with a protease inhibitor mixture was added and kept on ice for 2 h, and centrifuged at 4 °C. The lysates were placed on ice for 30 min and then centrifuged for 15 min at the speed of 12 000 rpm to remove cell debris. Subsequently, the protein concentration was determined by BCA (bicinchoninic acid protein assay). Total cellular proteins were resolved on a 12% SDS-PAGE, transferred to a PVDF membrane, and blocked with 5% skimmed milk in PBS. Then, the rabbit polyclonal antibody to EGR-1 (Sangon Biotech) was used as the primary antibody and incubated on the membrane at 4 °C for 12 h. Subsequently, the membrane was washed with PBS containing Tween-20 (0.1%) 3 times, followed by incubation with horseradish peroxidase-conjugated secondary antibody diluted to 1 : 2000. Finally, the membrane was washed 3 times and protein bands were visualized with the SuperSignal West Pico PLUS chemiluminescent substrate (Thermo Fisher Scientific). The analysis of reference protein GAPDH was the same as above.

### Apoptosis assays

Cell apoptosis was tested by the annexin V-FITC/PI assay. Briefly, the MDA-MB-231 cells were seeded in 1 mL of media in each well of a 12-well plate for 12 h, respectively. After removing the old solution, the cells were then treated with different samples and incubated for another 48 h. Next, the cells were harvested and treated with annexin V-FITC/PI according to the manufacturer's instructions and then examined by flow cytometry.

### *In vivo* fluorescence imaging

Male BALB/c mice were obtained from Hunan SJA Laboratory Animal Co. Ltd. They were 4–6 weeks old at the start of each experiment and allowed to acclimate in the laboratory for 1 week. All animal operations were in accord with the institutional animal use and care regulations, according to protocol No. SCXK (Xiang) 2013-0001, approved by the Laboratory Animal Center of Hunan Province.  $2 \times 10^6$  MDA-MB-231 cells (100  $\mu\text{L}$ ) were slowly injected into the thigh subcutaneous region of BALB/c nude mice. Tumors were then allowed to grow for 4–5 weeks to reach about 200 mm<sup>3</sup>. Before imaging, BALB/c nude mice were anesthetized to be motionless with anesthetics. The nude mice were then intratumorally injected with 30  $\mu\text{L}$  L-AuNCs/Dzs-Cy7 and T-AuNCs/Dzs-Cy7 (the concentration of Dzs was 1.5  $\mu\text{M}$ ) and time-lapse fluorescence imaging was carried out by using an IVIS Lumina II *in vivo* imaging system (Caliper Life Science, USA).

### *In vivo* anti-tumor efficacy evaluation

The anti-tumor efficacy of L-AuNCs/Dzs-Dox was evaluated using MDA-MB-231 tumor-bearing BALB/c nude mice. When the tumors exhibited a volume of  $\sim 100$  mm<sup>3</sup>, these mice were randomly divided into five groups (4 mice per sample) and injected with PBS, L-AuNCs/mDzs, L-AuNCs/Dzs, L-AuNCs/mDzs-Dox, and L-and AuNCs/Dzs-Dox, respectively. The dosage of Dox in the groups was 0.5 mg kg<sup>-1</sup>. Drugs were intratumorally injected every other day, and the body weight and



tumor volume of each mouse were recorded with calipers every other day. The tumor volume was calculated using the following equation:

$$\text{Tumor volume} = \text{Length} \times \text{Width}^2/2$$

On the 20th day, all mice were sacrificed and the collected tumors were used for H&E staining. The slices were imaged under a fluorescent inverted microscope.

### Statistical analysis

All experiments were conducted at least in triplicate. All data were expressed as the mean  $\pm$  standard deviation and analyzed using one-way analysis of variance (ANOVA) following Tukey's post-test. Differences with  $*P < 0.05$ ,  $**P < 0.01$ , and  $***P < 0.001$  were noted as statistically significant.

### Data availability

All experimental procedures, characterization data supporting this article have been described in the manuscript and uploaded as an ESI.† Original data shown in this paper are available from the corresponding author upon reasonable request.

### Author contributions

X. X. He and K. M. Wang conceived and supervised the project. H. H. Sun and W. J. Ma designed this experiments, performed the experiments and analyzed the data. S. D. Duan performed the western blot experiment. J. Huang, R. C. Jia, H. Cheng and B. Chen provided experimental advice. All authors contributed to ideation, discussion of results, and writing of the paper.

### Conflicts of interest

There are no conflicts of interest to declare.

### Acknowledgements

This work was supported by the Natural Science Foundation of China (21775036, 21675046, 21735002, 21521063, 21806186 and 21874035).

### Notes and references

- X. H. Wang, X. Y. Wang, S. X. Jin, M. Nafees and Z. J. Guo, *Chem. Rev.*, 2019, **119**, 1138–1192.
- Y. C. Wang, M. S. Shim, N. S. Levinson, H. W. Sung and Y. N. Xia, *Adv. Funct. Mater.*, 2014, **24**, 4206–4220.
- S. Ahmadi, N. Rabiee, M. Bagherzadeh, F. Elmi, Y. Fatahi, F. Farjadian, N. Baheiraei, B. Nasser, M. Rabiee, N. T. Dastjerd, A. Valibeik, M. Karimi and M. B. Hamblin, *Nano Today*, 2020, **34**, 100914.
- Z. H. Qing, J. Y. Xu, J. Zheng, L. He, Z. Zou, S. Yang, W. H. Tan and R. H. Yang, *Angew. Chem., Int. Ed.*, 2019, **58**, 11574–11585.
- M. Peng, *Theranostics*, 2020, **10**, 4557–4588.
- A. P. Blum, J. K. Kammeyer, A. M. Rush, C. E. Callmann and M. E. Hahn, *J. Am. Chem. Soc.*, 2020, **137**, 2140–2154.
- Y. F. Wang, W. Du, T. Zhang, Y. Zhu, Y. H. Ni, C. C. Wang, R. F. M. Sierra, L. W. Zou, L. S. Wang and G. L. Liang, *ACS Nano*, 2020, **14**, 9585–9593.
- Z. X. Jiang, B. Feng, J. Xu, T. P. Qing, P. Zhang and Z. H. Qing, *Biosens. Bioelectron.*, 2020, **166**, 112471.
- H. M. Wang, Y. Q. Chen, H. Wang, X. Q. Liu, X. Zhou and F. A. Wang, *Angew. Chem., Int. Ed.*, 2019, **58**, 7380–7384.
- Y. J. Liu, Z. Yan, F. Chan, A. Lee, J. L. Yin, R. Chung, J. B. Park, H. Rizos, W. Tao, M. M. Zheng, O. C. Farokhzad and B. Y. Shi, *Nano Lett.*, 2020, **20**, 1637–1646.
- Q. Lei, S. B. Wang, J. J. Hu, Y. X. Lin, C. H. Zhu, L. Rong and X. Z. Zhang, *ACS Nano*, 2017, **11**, 7201–7214.
- W. Hai, P. Agarwal, S. T. Zhao, J. H. Yu, X. B. Lu and X. M. He, *Adv. Mater.*, 2016, **28**, 347–355.
- L. J. Zhang, Y. Q. Qi, H. Min, C. Ni, F. Wang, B. Wang, H. Qin, Y. L. Zhang, G. N. Liu, Y. Qin, X. X. Duan, F. Li, X. X. Han, N. Tao, L. R. Zhang, Z. H. Qin, Y. Zhao and G. J. Nie, *ACS Nano*, 2019, **13**, 10852.
- J. C. Yang, Y. Shang, Y. H. Li, Y. Cui and X. B. Yin, *Chem. Sci.*, 2018, **9**, 7210–7217.
- L. Yang, H. Sun, Y. Liu, W. J. Hou, Y. Yang, R. Cai, C. Cui, P. H. Zhang, X. S. Pan, X. W. Li and L. Li, *Angew. Chem., Int. Ed.*, 2018, **57**, 17048–17052.
- D. Huo, S. Liu, C. Zhang, J. He, Z. Y. Zhou, H. Zhang and Y. Hu, *ACS Nano*, 2017, **11**, 10159–10174.
- Y. F. Lei, L. X. Tang, Y. Z. Y. Xie, Y. L. Xianyu, L. M. Zhang, P. Wang, Y. Hamada, K. Jiang, W. F. Zheng and X. Y. Jiang, *Nat. Commun.*, 2017, **8**, 15130.
- K. J. Chen, E. Y. Chaung, S. P. Wey, K. J. Lin, F. Cheng, C. C. Lin, H. L. Liu, H. W. Tseng, C. P. Liu, M. C. Wei, C. M. Liu and H. W. Sung, *ACS Nano*, 2014, **8**, 5105–5115.
- C. N. Loynachan, A. P. Soleimany, J. S. Dudani, Y. Y. Lin, A. Najer, A. Bekdemir and Q. Chen, *Nat. Nanotechnol.*, 2019, **14**, 883–890.
- U. Kauscher, M. N. Holm, M. Björnmalm and M. M. Stevens, *Adv. Drug Delivery Rev.*, 2019, **138**, 259–275.
- B. H. Zhu, L. Y. Wang, J. B. Huang, X. Xiang, Y. J. Tang, C. Cheng, Y. Feng, L. Ma and L. Qiu, *J. Mater. Chem. B*, 2019, **7**, 4581–4591.
- C. Y. Liu, K. K. Ewert, N. Wang, Y. L. Li, C. R. Safinya and W. H. Qiao, *Biomaterials*, 2019, **221**, 119412.
- Y. Z. Y. Xie, Y. L. Xianyu, N. X. Wang, Z. Y. Yan, L. Yong, Z. Zhu, N. S. Hatzakis and X. Y. Jiang, *Adv. Funct. Mater.*, 2018, **28**, 1702026.1–1702026.7.
- Y. Li, P. Li, R. Zhu, C. Luo, H. Li, S. F. Hu, Z. Nie, Y. Huang and S. Z. Yao, *Anal. Chem.*, 2016, **88**, 11184–11192.
- T. T. Jia, G. Yang, S. J. Mo, Z. Y. Wang, B. J. Li, W. Ma, Y. X. Guo, X. Y. Chen, X. L. Zhao, J. Q. Liu and S. Q. Zang, *ACS Omega*, 2020, **5**, 22702.
- H. L. Liu, G. S. Hong, Z. T. Luo, J. C. Chen, J. L. Chang, M. Gong, H. He, J. Yang, X. Yuan, L. L. Li, X. Y. Mu, J. Y. Wang, W. B. Mi, J. Luo, J. P. Xie and X. D. Zhang, *Adv. Mater.*, 2019, **31**, 1901015.



- 27 L. N. Yang, H. L. Wang, D. Y. Li, L. Li, X. F. Lou and H. L. Liu, *Chem. Mater.*, 2018, **30**(15), 5507–5515.
- 28 X. Yin, B. Yang, B. B. Chen, M. He and B. Hu, *Anal. Chem.*, 2019, **91**, 10596–10603.
- 29 Y. L. Wang, C. Xu, J. Zhai, F. P. Gao, R. Liu, L. Gao, Y. L. Zhao, Z. F. Chai and X. Y. Gao, *Anal. Chem.*, 2015, **87**, 343–345.
- 30 N. Goswami, Z. T. Luo, X. Yuan, D. T. Leong and J. P. Xie, *Mater. Horiz.*, 2017, **4**, 817.
- 31 C. S. Yun, A. Javier, T. Jennings, M. Fisher, S. Hira, S. Peterson, B. Hopkins, N. O. Reich and G. F. Strouse, *J. Am. Chem. Soc.*, 2005, **127**, 3115–3119.
- 32 T. L. Jennings, M. P. Singh and G. F. Strouse, *J. Am. Chem. Soc.*, 2006, **128**, 5462–5467.
- 33 Y. Z. Lu and W. Chen, *Chem. Soc. Rev.*, 2012, **41**, 3594–3623.
- 34 T. Chen, R. R. Nasaruddin, J. Xie and N. Yan, *Coord. Chem. Rev.*, 2018, **368**, 60–79.
- 35 G. H. Liang, X. D. Jin, S. X. Zhang and D. Xing, *Biomaterials*, 2017, **144**, 95–104.
- 36 Y. L. Wang, Y. Y. Cui, Y. L. Zhao, R. Liu, Z. P. Sun, W. Li and X. Y. Gao, *Chem. Commun.*, 2012, **48**, 871–873.
- 37 H. H. Sun, T. P. Qing, X. X. He, J. F. Shangguan, R. C. Jia, H. C. Bu, J. Huang and K. M. Wang, *Anal. Chim. Acta*, 2019, **1070**, 88–96.
- 38 C. P. Liu, T. H. Wu, Y. L. Lin, C. Y. Liu, S. Wang and S. Y. Lin, *Small*, 2016, **12**, 4127–4135.
- 39 C. Liu, C. Sun, H. Huang, K. Janda and T. Edgington, *Cancer Res.*, 2003, **63**, 2957–2964.
- 40 Y. J. Chen, S. C. Wu, C. Y. Chen, S. C. Tzou, T. L. Cheng, Y. F. Huang, S. S. Yuan and Y. M. Wang, *Biomaterials*, 2014, **35**, 304–315.
- 41 L. E. Edgington, M. Verdoes, A. Ortega, N. P. Withana, J. Lee, S. Syed, M. H. Bachmann, G. Blum and M. Bogyo, *J. Am. Chem. Soc.*, 2016, **135**, 174–182.
- 42 Z. Liu, M. Xiong, J. B. Gong, Y. Zhang, N. Bai, Y. P. Luo, L. Y. Li, Y. Q. Wei, Y. H. Liu, X. Y. Tan and R. Xiang, *Nat. Commun.*, 2014, **5**, 4280.
- 43 Z. Liu, L. S. Xiong, T. Li, P. L. Xie, Q. Li, B. L. Wang, L. Wang, L. L. Li, Y. Q. Wang, H. Chen and K. H. Nan, *Nanoscale*, 2016, **8**, 18400–18411.
- 44 Y. Zhao, Z. J. Hai, H. Y. Wang, L. H. Su and G. L. Liang, *Anal. Chem.*, 2018, **90**, 8732–8735.
- 45 L. J. Zhang, Y. Q. Qi, H. Min, C. Ni, F. Wang, B. Wang, H. Qin, Y. L. Zhang, G. N. Liu, Y. Qin, X. X. Duan, F. Li, X. X. Han, N. Tao, L. R. Zhang, Z. H. Qin, Y. Zhao and G. J. Nie, *ACS Nano*, 2019, **13**, 5091–5102.
- 46 G. Gasparini, P. C. Brooks, E. Biganzoli, P. B. Vermeulen and D. A. Cheresch, *Clin. Cancer Res.*, 1998, **4**, 2625–2634.
- 47 R. E. Holiday, *Biochem. J.*, 1936, **30**, 1795–1803.
- 48 F. S. Santiago, H. C. Lowe, M. M. Kavurma, C. N. Chesterman, A. Baker, D. G. Atkins and L. M. Khachigian, *Nat. Med.*, 1999, **5**, 1438.
- 49 G. Z. Zhu, J. Zheng, E. Q. Song, M. Donovan, K. J. Zhang, C. Liu and W. H. Tan, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, 7998–8003.

